The A$2.2B Myricx Bio Deal, AI's Healthcare Land Grab and Preventive Health
Novartis has agreed to acquire Myricx Bio for up to US$1.5 billion, approximately A$2.2 billion, in a major outcome for a UK biotech company with deep Australian venture backing.
In the inaugural What the Health Wrap, host Emily Casey is joined by Dr Jackie Rabec, co-founder and Chief Product Officer at ThinkMD.ai, and Dr Prashanth Rajan, Associate at Brandon Capital, to work through what the fortnight's biggest healthcare stories actually mean.
Prashanth explains how Myricx Bio evolved from small-molecule science into a new class of antibody-drug conjugate payloads. He discusses why the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.